These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7939422)

  • 1. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group.
    Krogsgaard K; Boesgaard S; Aldershvile J; Arendrup H; Mortensen SA; Petterson G
    Scand J Infect Dis; 1994; 26(3):239-47. PubMed ID: 7939422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
    Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
    Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the incidence of cytomegalovirus disease following heart transplantation decreased by prophylactic ganciclovir and CMV-hyperimmunglobulin?
    Cantarovich M; René P; Latter D
    Transpl Int; 1994; 7 Suppl 1():S385-8. PubMed ID: 11271260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
    Chitasombat MN; Watcharananan SP
    F1000Res; 2018; 7():1568. PubMed ID: 30473779
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus infection rate among heart transplant patients in relation to the potency of antithymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group.
    Krogsgaard K; Boesgaard S; Aldershvile J; Arendrup H; Mortensen SA; Petterson G
    Transplant Proc; 1994 Jun; 26(3):1718. PubMed ID: 8030099
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated?
    Elkins CC; Frist WH; Dummer JS; Stewart JR; Merrill WH; Carden KA; Bender HW
    Ann Thorac Surg; 1993 Dec; 56(6):1267-72; discussion 1272-3. PubMed ID: 8267423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation.
    Abou-Jaoude MM; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1089-94. PubMed ID: 12835082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies.
    Goussetis E; Efstathiou E; Paisiou A; Avgerinou G; Zisaki K; Giamouris VJ; Peristeri I; Kitra V; Vessalas G; Gamaletsou MN; Sipsas NV; Graphakos S
    Transpl Infect Dis; 2015 Apr; 17(2):201-7. PubMed ID: 25645592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation.
    Clinckart F; Bulpa P; Jamart J; Eucher P; Delaunois L; Evrard P
    Transplant Proc; 2009 Mar; 41(2):607-9. PubMed ID: 19328937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
    Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
    Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
    Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
    Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy.
    Preiksaitis JK; Rosno S; Grumet C; Merigan TC
    J Infect Dis; 1983 Jun; 147(6):974-81. PubMed ID: 6304206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of cytomegalovirus infection following heart transplantation].
    Laske A; Carrel T; Niederhäuser U; Bauer E; Pasic M; von Segesser LK; Gallino A; Turina M
    Helv Chir Acta; 1992 Jan; 58(4):527-32. PubMed ID: 1316336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.